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Hypocretins (hcrt), also known as orexins, play a critical role in reward-seeking behavior for
natural rewards and drugs of abuse. The mesolimbic dopamine pathway that projects from
the ventral tegmental area (VTA) to the nucleus accumbens (NAc) is critically involved in
the neural mechanisms underlying reward-seeking and motivation. Hcrt immunopositive
fibers densely project to the shell of the nucleus accumbens (NAcSh), suggesting that
the NAcSh might be a site for the interaction between hcrt and dopaminergic modulation
of reward-seeking behavior. While it is known that hcrt action in the VTA can increase
dopamine in the NAc, it has not been determined if hcrt released locally at dopaminergic
terminals in the NAcSh can modulate dopamine concentration. Here, we use fast scan
cyclic voltammetry (FSCV) in forebrain slices containing the NAcSh to determine whether
hcrt can alter evoked dopamine concentration. We found bath application of hcrt-1
increases phasically evoked dopamine release, without altering reuptake at dopamine
terminals in the NAcSh. Hcrt-1-induced potentiation of dopamine concentration was
inhibited by SB334867, a hcrt receptor 1 antagonist, as well as ionotropic glutamate
receptor antagonists, AP-5, CNQX and DNQX. Taken together, these results suggest that
local hcrt-1 can modulate dopamine in the NAcSh and may play a role in reward-seeking
and appetitive behaviors.
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INTRODUCTION
The hypocretins (hcrt), also known as orexins, are neuropeptides
produced solely in the lateral hypothalamic and perifornical areas
(de Lecea et al., 1998; Sakurai et al., 1998). They are comprised
of two distinct peptides; hypocretin-1 (hcrt-1) and hypocretin-2
(hcrt-2). Hypocretins activate two known G-protein coupled
receptors, hcrt receptor 1 (hcrt-R1) and hcrt receptor 2 (hcrt-R2).
Hypocretin neurons project locally within the hypothalamus and
widely throughout the brain, suggesting hypocretin involvement
in multiple physiological functions. Indeed, hypocretin has been
implicated in sleep and wakefulness, energy homeostasis and
addiction (Aston-Jones et al., 2009; Boutrel et al., 2010).
Dopamine neurons of the ventral tegmental area (VTA)
project to the nucleus accumbens (NAc) via the medial forebrain
bundle (Nauta et al., 1978). Tonic and phasic activity of dopamine
neurons can promote dopamine release in NAc (Tsai et al., 2009).
Phasic firing typically accompanies reward-predicting cues lead-
ing to reward seeking behaviors (Phillips et al., 2003; Roitman
et al., 2004; Day et al., 2007; Tsai et al., 2009). The NAc receives
excitatory glutamatergic inputs primarily from cortical and lim-
bic structures, including the hippocampus, basolateral amygdala,
prefrontal cortex, and various thalamic nuclei (Sesack et al.,
1989; Berendse and Groenewegen, 1990; Callaway et al., 1991;
Pennartz et al., 1994; Finch, 1996). While glutamatergic and
dopaminergic inputs converge on the sameMSNs, direct synaptic
contacts between dopaminergic and glutamatergic axon termi-
nals have not been observed in the NAc (Sesack and Pickel, 1990,
1992; O’Donnell and Grace, 1995; Mulder et al., 1998). The NAc
consists of two anatomically, biochemically, and behaviorally dis-
tinct subregions referred to as the shell (NAcSh) and the core
(Meredith et al., 1992, 1993, 2008; Sesack and Grace, 2010).
Hypocretin neurons make dense projections to both dopamine
neurons of the VTA as well as the medial NAcSh (Peyron et al.,
1998; Baldo et al., 2003) where both hcrt-R1 and R2 are expressed
(Marcus et al., 2001; Martin et al., 2002).
Many reports have demonstrated that hcrt-1 signaling in the
VTA promotes reward-seeking behaviors, including reinstate-
ment of extinguished drug seeking behavior (Harris et al., 2005;
Wang et al., 2009; James et al., 2011), behavioral sensitization to
cocaine (Borgland et al., 2006) or effort for sucrose, high fat or
cocaine (España et al., 2010; Thompson and Borgland, 2011).
Hcrt-1 increases dopamine neuronal firing (Korotkova et al.,
2003; Muschamp et al., 2007; Moorman and Aston-Jones, 2010)
and potentiates excitatory synaptic transmission onto dopamine
neurons in the VTA (Borgland et al., 2006, 2009), a mecha-
nism thought to promote arousal for salient events (Borgland
et al., 2009; Thompson and Borgland, 2011). Hcrt-1 action
in the NAcSh inhibits N-methyl-D-aspartate (NMDA)-induced
currents in isolated medium neurons (MSNs; Martin et al.,
2002). However, other reports suggest that hcrt-1 or hcrt-2 dose-
dependently depolarizes (Mukai et al., 2009) and increases firing
rate of MSNs in slices containing the NAcSh (Mukai et al., 2009;
Mori et al., 2011). Hcrt-1 administered directly to the NAcSh pro-
motes feeding and locomotor activity (Thorpe and Kotz, 2005)
as well as dopamine-dependent turning behavior (Kotani et al.,
2008).
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Hcrt-1 in the VTA increases dopamine release in the NAc and
prefrontal cortex (Narita et al., 2006; Vittoz and Berridge, 2006;
Vittoz et al., 2008; España et al., 2011). Moreover, hcrt-1 in the
VTA enhances cocaine-induced dopamine release (España et al.,
2011). However, it is unknown if hcrt-1 within the NAcSh can
modulate extracellular dopamine concentration [DA]o. Here, we
tested the hypothesis that hcrt-1 increases evoked [DA]o in the
NAcSh using Fast Scan Cyclic Voltammetry (FSCV) at single pulse
or phasic burst-like stimulation frequencies.
MATERIALS AND METHODS
ANIMALS
All protocols were in accordance with the ethical guidelines
established by the Canadian Council for Animal Care and were
approved by the University of British Columbia Animal Care
Committee. C57BL/6J mice were obtained from the University of
British Columbia breeding facility.
SLICE PREPARATION
Male C57BL/2J mice (25–30 g) were anesthetized with halothane
or isoflurane, decapitated, and brains were extracted and pre-
pared for slicing. Coronal slices (250μm) containing the
NAcSh were cut in ice-cold sucrose-containing artificial cere-
brospinal fluid (aCSF) solution ([mM]: 87 NaCl, 2.5 KCl, 1.25
NaH2PO4, 25 NaHCO3, 7 MgCl2, 0.95 CaCl2, 75 sucrose)
saturated with 95% O2/5% CO2 using a vibratome (Leica,
Nussloch, Germany). Slices were incubated in warm (31.5◦C)
95% O2/5% CO2 oxygenated aCSF ([mM]: 119 NaCl, 1.6
KCl, 1.0 NaH2PO4, 26.2 NaHCO3, 1.3 MgCl2, 2.5 CaCl2,
11 glucose; pH = 7.4) for at least 1 h and transferred to
a recording chamber that was constantly perfused (gravity
flow: 1.5ml/min) with oxygenated aCSF (30–32◦C). The slices
were allowed to equilibrate in the recording chamber with
the superfusion medium for an additional 20–30min before
experimentation.
FAST-SCAN CYCLIC VOLTAMMETRY
Evoked [DA]o was measured using FSCV with carbon-fiber
microelectrodes. Carbon fibers (7μm diameter; Goodfellow)
were pulled in glass electrodes and cut to a final exposed length
of ∼150μm. Triangular waveforms (holding at −0.4 V) at 10Hz
(−0.4 to 1.0 V vs. Ag/AgCl at 400V/s scan rate) were used.
Catecholamine release was evoked using electrical stimulation
applied with a bipolar stimulating electrode positioned flush with
the tissue for local surface stimulation. To evoke [DA]o in the
NAcSh, either a single pulse was delivered or 100Hz, 5 pulses
to mimic phasic dopamine release (Rice and Cragg, 2004). The
voltammetric electrode was positioned between the tips with the
aid of a binocular microscope, and then lowered 50–100μm into
the tissue. Dopamine was identified by characteristic oxidation
and reduction peak potentials (approx. +600 and −200mV vs.
Ag/AgCl). To determine the time course of dopamine, the cur-
rent at the peak oxidation was plotted against time. Relative
electrode sensitivities for dopamine were determined by obtain-
ing voltammograms from exogenous application of dopamine
(0.1–1μM) made from stock solutions in 0.1M HClO4 imme-
diately before use.
DRUGS
Hcrt-1 or AP-5 was purchased from Tocris (Ellisville), reconsti-
tuted in ddH20 and stored in aliquots at −20◦C. Ten minutes
prior to drug application aliquots were thawed and diluted to the
working concentration in aCSF buffer. CNQX or DNQXwas pur-
chased from Sigma (Oakville) reconstituted in DMSO and stored
in aliquots, protected from light, at −20◦C. Prior to the experi-
ment, these compounds were diluted in aCSF and used at 1/1000
working concentrations of DMSO. SB334867 was purchased from
Tocris (Ellisville) reconstituted in DMSO and stored in aliquots
at −20◦C. Prior to the experiment, SB334867 was diluted in aCSF
and used at 1/1000 working concentrations of DMSO. Our previ-
ous work has demonstrated that 1/1000DMSOdoes not influence
evoked [DA]o (Mebel et al., 2012).
STATISTICS
Values listed are means ± SEM. Statistical significance was
assessed using a paired student t-test comparing a time-point
on the baseline prior to drug application to a time-point after
drug application. For multiple comparisons, One-Way ANOVA
was used unless otherwise indicated. A difference of p < 0.05
was considered significant. Statistical tests were performed with
GraphPad Prism v.5.
RESULTS
Hcrt-1 DOES NOT MODIFY SINGLE PULSE EVOKED [DA]o AT
TERMINALS
To determine if hcrt-1 could modulate [DA]o at dopaminergic
terminals in the NAcSh where there is significant density of hcrt-
immunopositive axonal fibers (Baldo et al., 2003), we applied
hcrt-1 (100 nM) for 5min to slices while evoking dopamine with
a single pulse every 2min. Hcrt-1 did not significantly alter the
oxidation potential of dopamine (Figure 1A) or the maximal
release of dopamine (Figure 1B; baseline: 101 ± 3% vs. 15min
after hcrt-1: 96 ± 4%, n = 7; P > 0.05). No significant change
occurred in evoked [DA]o over the duration of the experiment
in the absence of hcrt-1 (Figure 1B; baseline: 96 ± 3% vs: 15min
after vehicle aCSF application: 95 ± 7%, n = 5; P > 0.05). The
decay of the current, represented by tau (τ), has been demon-
strated to be positively correlated with Km, suggesting that τ
is an appropriate measurement of dopamine uptake (Yorgason
et al., 2011). Averaged current-time plots of evoked [DA]o indi-
cated that hcrt-1 did not significantly modify dopamine uptake
under single pulse conditions (Figures 1C,D, τbaseline = 0.41 ±
0.05 s, τhcrt−1 = 0.43 ± 0.05 s; n = 7; P > 0.05). Decay of evoked
dopamine did not significantly change over the course of the
experiment in the absence of hcrt-1 (τbaseline = 0.44 ± 0.09 s,
τaCSF = 0.41 ± 0.07 s; n = 5; P > 0.05).
Hcrt-1 INCREASES PHASIC [DA]o AT TERMINALS
Phasic dopamine release accompanies reward-predicting stimuli
(Phillips et al., 2003; Roitman et al., 2004; Day et al., 2007). To
test if hcrt-1 was able to modulate terminal [DA]o under phasic
conditions, we evoked dopamine release every 5min with 100Hz,
5 pulses, a parameter which increases dopamine concentration
relative to a single pulse (Rice and Cragg, 2004). As reported pre-
viously, we observed an 5.5 fold increase in [DA]o with phasic
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FIGURE 1 | Hcrt-1 does not modify single pulse dopamine in the NAcSh.
[DA]o was electrically evoked using a single pulse in slices containing the
NAcSh. (A) An example voltammogram from a single experiment for
electrically evoked [DA]o before (black line) and immediately after a 5min
hcrt-1 (100 nM, grey line) application. (B) Bath application of hcrt-1 (100 nM,
5min, filled circles) did not modify evoked [DA]o in NAcSh slices (n = 6)
compared to control slices (n = 5, open circles) (P < 0.05). (C) A
representative current-time plot from a single experiment showing [DA]o
evoked before (open black line) and 15min after (grey line) application of
hcrt-1 (100 nM). (D) The signal decay was fit with a one phase exponential
curve to determine the rate of decay 5min before and 15min after
immediately after hcrt-1 application. The rate of decay, Tau (τ), before and
after hcrt-1 application was not significantly different (P > 0.05, n = 6). Bars
represent mean and SEM.
stimulation (4.2 ± 1.6μM, n = 13) compared to a single pulse
(0.8 ± 0.2μM, n = 6; Patel et al., 1992; Rice and Cragg, 2004).
Interestingly, hcrt-1 increased [DA]o in NAcSh slices with a slow
time course, reaching a maximum at 25min after hcrt-1 applica-
tion (Figures 2A,B,C, baseline: 99 ± 2% vs. 25min after hcrt-1:
137 ± 12%, n = 10, P < 0.05). To test if peak [DA]o was altered
during hcrt-1 application, we evoked [DA]o 2.5min after initi-
ation of the 5min bath application. Surprisingly, there was no
significant increase in phasically evoked [DA]o immediately after
hcrt-1 application (baseline: 99 ± 4 vs. hcrt-1: 108 ± 5%, n = 5,
P > 0.05). To determine if the increase in [DA]o was due to a
change in uptake, we measured the decay of evoked DA under
phasic conditions. There was no significant difference in τ 25min
after application of hcrt-1 (Figure 2D, τbaseline = 0.46 ± 0.05 s,
τhcrt−1 = 0.53 ± 0.07 s; n = 10; P > 0.05). Taken together, these
results suggest that hcrt-1 increases dopamine release only under
phasic release conditions.
To determine if hcrt-1-induced potentiation of striatal [DA]o
required activation of hcrt-R1, we applied hcrt-1 in the pres-
ence of the hcrt-R1 antagonist, SB334867 (1μM) while evoking
[DA]o under phasic conditions. In slices preincubated for 30min
with SB334867, hcrt-1 did not alter phasically evoked [DA]o
(Figures 3A,B, immediately prior to hcrt-1: 97 ± 2%; 25min
after hcrt-1 application: 94 ± 3%, n = 4, P > 0.05), suggesting
that striatal hcrt-R1s are required for hcrt-1-mediated potentia-
tion of [DA]o.
Interestingly, hcrt-1 modulation of dopamine release occurs
only under phasic conditions and not single pulse, suggesting
that hcrt-1 may not be directly modulating dopamine terminals
to promote release. One possibility is that hcrt-1 could be act-
ing at its receptors on glutamatergic terminals within the NAcSh
to increase dopamine release indirectly. To test the contribu-
tion of glutamatergic signaling to hcrt-1 modulation of [DA]o
in the NAcSh, we repeated the experiment in the presence of
CNQX (10μM) and AP-5 (50μM) to block α-amino-3-hydroxy-
5-methylisoxazole-4-propionate (AMPA)/Kainate and NMDA
receptors, respectively. Application of excitatory amino acid
receptor antagonists significantly attenuated phasically evoked
dopamine by 12 ± 4% (Figures 4A,B,C; baseline: 100 ± 2% vs.
CNQX/AP-5: 89 ± 4%, n = 6, P < 0.05). The effect of hcrt-1
on [DA]o was abolished in the presence of CNQX and AP-
5 (Figures 4A,B,C, 25min after hcrt-1 application: 91 ± 4%,
n = 6, P > 0.05). Application of the AMPA/Kainate recep-
tor antagonist, DNQX, inhibited phasically evoked dopamine by
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FIGURE 2 | Hcrt-1 increases phasic dopamine in the NAcSh. Phasic [DA]o
was electrically evoked using 100Hz, 5 pulses in slices containing the NAcSh.
(A) An example voltammogram from a single experiment for electrically
evoked [DA]o before (black line) and immediately after a 5min hcrt-1 (100 nM,
grey line) application. (B) Bath application of hcrt-1 (100 nM, 5min, filled
circles) significantly increased evoked [DA]o in NAcSh slices (n = 11)
compared to control slices (n = 6, open circles) (∗P < 0.05). (C) A
representative current-time plot from a single experiment showing [DA]o
evoked before (open black line) and 25min after (grey line) application of
hcrt-1 (100 nM). (D) The signal decay was fit with a one phase exponential
curve to determine the rate of decay 5min before and 25min after
immediately after hcrt-1 application. Tau before and after hcrt-1 application
was not significantly different (P > 0.05, n = 11). Bars represent mean
and SEM.
A B
FIGURE 3 | Hcrt-1 modulation of phasic dopamine in the NAcSh is
mediated by hcrt-R1. Phasic [DA]o was electrically evoked using
100Hz, 5 pulses in slices containing the NAcSh. Slices were
preincubated with SB 334967 (1μM) for 30min prior to application of
hcrt-1 and throughout the experiment. (A) An example
voltammogram from a single experiment for electrically evoked [DA]o
before (black line) and 25min after a 5min hcrt-1 (100 nM, grey line)
application. (B) In the presence of SB 334867, bath application of hcrt-1
(100 nM, 5min) did not significantly alter evoked [DA]o in NAcSh slices
(n = 4; P > 0.05).
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FIGURE 4 | Hcrt-1 modulation of phasic dopamine in the NAcSh requires
glutamatergic signaling. Phasic [DA]o was electrically evoked using 100Hz,
5 pulses in slices containing the NAcSh. (A) CNQX (10μM) and AP5 (50μM)
were bath applied to slices for 20min prior to application of hcrt-1 and
throughout the experiment. An example voltammogram from a single
experiment for electrically evoked [DA]o before (hatched line), during CNQX
and AP5 treatment (black line) and 25min after a 5min hcrt-1 (100 nM, grey
line) application. (B) CNQX and AP5 significantly reduced [DA]o in NAcSh
slices (P < 0.05). In the presence of CNQX and AP5, bath application of hcrt-1
(100 nM, 5min) did not significantly alter evoked [DA]o in NAcSh slices (n = 7;
P > 0.05). (C) A bargraph demonstrating maximal effects relative to baseline
(open bar) of CNQX and AP5 treatment with (filled bar) or without hcrt-1
(shaded bar). CNQX and AP5 with or without hcrt-1 was significantly different
from baseline (repeated measures ANOVA with a tukey’s post hoc test (n = 7;
P < 0.05). (D) An example voltammogram from a single experiment for
electrically evoked [DA]o before (hatch line), during DNQX treatment (black
line) and 25min after a 5min hcrt-1 (100 nM, grey line) application. (E) DNQX
significantly reduced [DA]o in NAcSh slices (P < 0.05). In the presence of
DNQX, bath application of hcrt-1 (100 nM, 5min) did not significantly alter
evoked [DA]o in NAcSh slices (n = 5; P > 0.05). (F) A bar graph demonstrating
maximal effects relative to baseline (open bar) of DNQX treatment with (filled
bar) or without hcrt-1 (shaded bar). DNQX with or without hcrt-1 was
significantly different from baseline (repeated measures ANOVAwith a tukey’s
post hoc test (n = 5; P < 0.05). Bars represent means and SEM. ∗p < 0.05.
14 ± 2% (Figures 4D,E,F; baseline: 100 ± 1% vs. DNQX: 85 ±
4%, n = 5, P < 0.05). The effect of hcrt-1 on [DA]o was also
abolished in the presence of DNQX (Figures 4D,E,F; 25min after
hcrt-1 application: 87 ± 5%, n = 5, P > 0.05). Taken together,
these data suggest that hcrt-1 activation of glutamatergic inputs is
required for hcrt-1-mediated increase in dopamine release under
phasic conditions.
DISCUSSION
While several studies have demonstrated that hcrt-1 adminis-
tered into the VTA can increase dopamine concentration in the
NAcSh (Vittoz et al., 2008), NAc core (España et al., 2011)
or both (Narita et al., 2006), our data suggests an additional
mechanism by which hcrt-1 can modulate dopamine concen-
trations in the NAcSh. We demonstrate that hcrt-1 promotes
local dopamine release in NAcSh slices, suggesting that direct
projections of hcrt neurons from the lateral hypothalamus can
modulate dopamine release onto medium spiny neurons of the
NAcSh. Notably hcrt-1-induced increase of [DA]o under phasic
conditions reached a maximum 15 after hcrt-1 application. This
delayed effect is likely due to the necessity for the 33 amino acid
peptide to penetrate the tissue to reach its receptors. Interestingly,
hcrt-1 modulates NMDA receptors on VTA dopamine neurons
with a similar time course (Borgland et al., 2006). Hcrt-1 potenti-
ation of local [DA]o was due to an increase in dopamine release as
opposed to modulation of reuptake mechanisms as there was no
effect of hcrt-1 on the decay of evoked dopamine. Taken together,
in addition to hcrt-1 acting at the VTA to increase dopamine con-
centration in the NAc, hcrt-1 can also act at terminals to modulate
release.
We observed that hcrt-1 modulated evoked [DA]o under pha-
sic conditions, but not after a single pulse repeated every 2min.
Therefore, it is likely that hcrt-1 is acting indirectly in the NAcSh
to increase terminal dopamine release. One possibility is that
hcrt-1 modulates GABAergic activity onto dopamine terminals
in the NAcSh.While it has not been demonstrated how dopamine
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concentration is modulated by GABA in the NAcSh, GABA is
reported to increase [DA]o in the dorsal striatum (Avshalumov
et al., 2003). Alternatively, hcrt-1 may act on glutamatergic inputs
in the NAcSh to modulate [DA]o. Consistent with this idea,
we demonstrated that application of AMPA or NMDA receptor
antagonists inhibited a hcrt-1-induced increase of [DA]o.
Dopamine spillover from dopaminergic synapses onto MSNs
not only activates receptors on MSNs several micrometers away
(Garris et al., 1994; Gonon, 1997; Gonon et al., 2000), but may
also activate presynaptic dopamine receptors on neighboring
glutamatergic afferents (Wang and Pickel, 2002). Furthermore,
glutamate released from excitatory inputs in the NAc can also
modulate dopamine release, although its effects are complicated
by the heterogeneity of expression and location of ionotropic and
metabotropic glutamate receptors. There is a large body of evi-
dence suggesting that glutamate is excitatory toward dopamine
release (Cheramy et al., 1986; Clow and Jhamandas, 1988; Kalivas
et al., 1989; Leviel et al., 1990; Carrozza et al., 1992; Desce
et al., 1992; Jin and Fredholm, 1997; Borland and Michael, 2004).
However, these studies mainly employ use of microdialysis tech-
niques or dopamine release from isolated cells or synaptosomes.
Using FSCV in NAcSh slices, we demonstrate that application
of ionotropic glutamate receptor antagonists, AP-5 and CNQX
or DNQX alone, significantly inhibited phasically evoked [DA]o.
In contrast to the present study, phasically evoked dopamine
from dorsal striatum slices was increased in the presence of
the AMPA receptor antagonist, GYKI-52466 (Avshalumov et al.,
2003, 2008), the NMDA receptor antagonist, AP-5 or the broad
spectrum ionotropic glutamate receptor antagonist, kynurenate
(Wu et al., 2000). Moreover, glutamate spillover can activate
metabotropic glutamate receptors to inhibit evoked dopamine
(Zhang and Sulzer, 2003). A possible reason for the discrepancy
between our study and the other studies employing FSCV in slices
is that the distribution of ionotropic receptors and glutamatergic
inputs may differ between dorsal striatum and NAcSh (Pennartz
et al., 1994; Sesack and Grace, 2010). Indeed, NMDA or AMPA
receptors increase dopamine efflux in a study employing in vivo
voltammetry in the NAc (Svensson et al., 1994) and that DNQX
can inhibit quisqualate evoked dopamine concentration in a study
employing microdialysis in the NAc (Imperato et al., 1990).
Hcrt-1 acts with similar efficacy at both hcrt-R1 and hcrt-
R2 (Sakurai et al., 1998). Because hcrt-1 has been implicated in
addiction-related behaviors and modulation of dopamine via its
action in the VTA, we were interested in testing if this peptide
altered local dopamine release at axon terminals. Interestingly,
the hcrt-1-mediated increase in NAcSh dopamine was inhibited
by SB 334867, suggesting this effect was mediated by hcrt-R1.
Hcrt-R2, and to a lesser extent hcrt-R1 are expressed within the
NAcSh (Trivedi et al., 1998; Marcus et al., 2001; Martin et al.,
2002). Notably, cell bodies of glutamatergic neuron that project
to the NAcSh, including the prefrontal cortex and basolateral
amydala, express hcrt-R1 (Trivedi et al., 1998; Lu et al., 2000;
Marcus et al., 2001) and it is possible that their axon termi-
nals may also express hcrt-R1. Furthermore, hcrt-1 promotion of
glutamate release has been demonstrated in other brain regions
such as the VTA (Borgland et al., 2006, 2009; Wang et al., 2009),
amygdala (John et al., 2003) and hippocampus (Stanley and
Fadel, 2011). Therefore, it is feasible that activation of hcrt-R1s
on glutamatergic inputs in the NAcSh can increase glutamate
release. Our results support the possibility that hcrt-R1 activa-
tion on glutamatergic inputs can promote dopamine release in
the NAcSh.
Dense staining of hcrt terminals in the NAcSh has been
observed (Peyron et al., 1998; Baldo et al., 2003), suggest-
ing that hcrt-1 has direct action in the NAc. Local action
of hcrt-1 at dopaminergic terminals may potentiate effects of
hcrt-1-mediated dopamine release via its action in the VTA.
Indeed, other studies have demonstrated that application of
hcrt-1 or hcrt-2 into the NAcSh can potentiate dopaminergic
activity. For example, in NAcSh slices, when hcrt-2 was co-applied
with dopamine, its effect on firing rate was significantly poten-
tiated in 2/3 of MSNs when compared to hcrt-2-induced or
dopamine-induced firing alone (Mori et al., 2011). Another study
demonstrated that hcrt-1 or hcrt-2 administered directly in the
NAcSh potentiated the effects of dopamine receptor agonists on
contraversive pivoting behavior (Kotani et al., 2008). Thus, con-
sistent with our study, it is likely that an interaction between hcrt
and dopaminergic systems for reward seeking behaviormay occur
in the NAcSh. Furthermore, one can speculate that local action
of hcrt-1 in the NAcSh may potentiate dopaminergic responses
mediated by hcrt-1 or other drug action in the VTA. In summary,
hcrt-1 increased phasically evoked [DA]o in the NAcSh. This
effect required activation of AMPA receptors and hcrt-R1. This
study demonstrates an additional mechanism by which hcrt-1 can
modulate dopamine release and potentially influence appetitive
behaviors.
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